Emilio Alba-rekin lankidetzan egindako argitalpenak (38)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  2. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

    New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  4. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 2, pp. 462-470

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

  3. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2015

  1. Defining breast cancer intrinsic subtypes by quantitative receptor expression

    Oncologist, Vol. 20, Núm. 5, pp. 474-482

2014

  1. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: Results from the GEICAM 9906 trial

    Breast Cancer Research, Vol. 16, Núm. 2

  2. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 231-237

  3. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2013

  1. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis

    Breast Cancer Research, Vol. 15, Núm. 6

  2. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

    Critical Reviews in Oncology/Hematology, Vol. 85, Núm. 3, pp. 315-331

2012

  1. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

    BMC Medical Genomics, Vol. 5